Exploring the dependencies between multimodal brain networks and integrating node features to enhance brain disease diagnosis remains a significant challenge. Some work has examined only brain connectivity changes in patients, ignoring important information about radiomics features such as shape and texture of individual brain regions in structural images. To this end, this study proposed a novel deep learning approach to integrate multimodal brain connectome information and regional radiomics features for brain disease diagnosis. A dual-branch autoencoder (ConnectomeAE) based on multimodal brain connectomes was proposed for brain disease diagnosis. Specifically, a matrix of radiomics feature extracted from structural magnetic resonance image (MRI) was used as Rad_AE branch inputs for learning important brain region features. Functional brain network built from functional MRI image was used as inputs to Cycle_AE for capturing brain disease-related connections. By separately learning node features and connection features from multimodal brain networks, the method demonstrates strong adaptability in diagnosing different brain diseases. ConnectomeAE was validated on two publicly available datasets. The experimental results show that ConnectomeAE achieved excellent diagnostic performance with an accuracy of 70.7 % for autism spectrum disorder and 90.5 % for Alzheimer's disease. A comparison of training time with other methods indicated that ConnectomeAE exhibits simplicity and efficiency suitable for clinical applications. Furthermore, the interpretability analysis of the model aligned with previous studies, further supporting the biological basis of ConnectomeAE. ConnectomeAE could effectively leverage the complementary information between multimodal brain connectomes for brain disease diagnosis. By separately learning radiomic node features and connectivity features, ConnectomeAE demonstrated good adaptability to different brain disease classification tasks.

Despite the widespread use of stereotactic radiosurgery (SRS) to treat cerebral arteriovenous malformations (AVMs), this procedure can lead to radiation-induced changes (RICs) in the surrounding brain tissue. Volumetric assessment of RICs is crucial for therapy planning and monitoring. RICs that appear as hyper-dense areas in magnetic resonance T2-weighted (T2w) images are clearly identifiable; however, physicians lack tools for the segmentation and quantification of these areas. This paper presents an algorithm to calculate the volume of RICs in patients with AVMs following SRS. The algorithm could be used to predict the course of RICs and facilitate clinical management. We trained a Mask Region-based Convolutional Neural Network (Mask R-CNN) as an alternative to manual pre-processing in designating regions of interest. We also applied transfer learning to the DeepMedic deep learning model to facilitate the automatic segmentation and quantification of AVM edema regions in T2w images. The resulting quantitative findings were used to explore the effects of SRS treatment among 28 patients with unruptured AVMs based on 139 regularly tracked T2w scans. The actual range of RICs in the T2w images was labeled manually by a clinical radiologist to serve as the gold standard in supervised learning. The trained model was tasked with segmenting the test set for comparison with the manual segmentation results. The average Dice similarity coefficient in these comparisons was 71.8%. The proposed segmentation algorithm achieved results on par with conventional manual calculations in determining the volume of RICs, which were shown to peak at the end of the first year after SRS and then gradually decrease. These findings have the potential to enhance clinical decision-making. Not applicable.

Vestibular schwannomas (VS) are benign tumors that can lead to hearing loss, balance issues, and tinnitus. Gamma Knife Radiosurgery (GKS) is a common treatment for VS, aimed at halting tumor growth and preserving neurological function. Accurate monitoring of VS volume before and after GKS is essential for assessing treatment efficacy. To evaluate the accuracy of an artificial intelligence (AI) algorithm, originally developed to identify NF2-SWN-related VS, in segmenting non-NF2-SWN-related VS and detecting volume changes pre- and post-GKS. We hypothesize this AI algorithm, trained on NF2-SWN-related VS data, will accurately apply to non-NF2-SWN VS and VS treated with GKS. In this retrospective cohort study, we reviewed data from an established Gamma Knife database, identifying 16 patients who underwent GKS for VS and had pre- and post-GKS scans. Contrast-enhanced T1-weighted MRI scans were analyzed with both manual segmentation and the AI algorithm. DICE similarity coefficients were computed to compare AI and manual segmentations, and a paired t-test was used to assess statistical significance. Volume changes for pre- and post-GKS scans were calculated for both segmentation methods. The mean DICE score between AI and manual segmentations was 0.91 (range 0.79-0.97). Pre- and post-GKS DICE scores were 0.91 (range 0.79-0.97) and 0.92 (range 0.81-0.97), indicating high spatial overlap. AI-segmented VS volumes pre- and post-GKS were consistent with manual measurements, with high DICE scores indicating strong spatial overlap. The AI algorithm processed scans within 5 min, suggesting it offers a reliable, efficient alternative for clinical monitoring. DICE scores showed high similarity between manual and AI segmentations. The pre- and post-GKS VS volume percentage changes were also similar between manual and AI-segmented VS volumes, indicating that our AI algorithm can accurately detect changes in tumor growth.

Some sarcomas are highly malignant, associated with high recurrence despite treatment. This multicenter study aimed to develop and validate a radiomics signature to estimate sarcoma progression-free survival (PFS). The study retrospectively enrolled 202 consecutive patients with pathologically diagnosed sarcoma, who had pre-treatment axial fat-suppressed T2-weighted images (FS-T2WI), and included them in the ROI-Net model for training. Among them, 120 patients were included in the radiomics analysis, all of whom had pre-treatment axial T1-weighted and transverse FS-T2WI images, and were randomly divided into a development group (n = 96) and a validation group (n = 24). In the development cohort, Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression was used to develop the radiomics features for PFS prediction. By combining significant clinical features with radiomics features, a nomogram was constructed using Cox regression. The proposed ROI-Net framework achieved a Dice coefficient of 0.820 (0.791-0.848). The radiomics signature based on 21 features could distinguish high-risk patients with poor PFS. Univariate Cox analysis revealed that peritumoral edema, metastases, and the radiomics score were associated with poor PFS and were included in the construction of the nomogram. The Radiomics-T1WI-Clinical model exhibited the best performance, with AUC values of 0.947, 0.907, and 0.924 at 300 days, 600 days, and 900 days, respectively. The proposed ROI-Net framework demonstrated high consistency between its segmentation results and expert annotations. The radiomics features and the combined nomogram have the potential to aid in predicting PFS for patients with sarcoma.

Cognitive decline is common in End-Stage Renal Disease (ESRD) patients, yet its neural mechanisms are poorly understood. This study investigates structural and functional brain network reconfiguration in ESRD patients transitioning to Mild Cognitive Impairment (MCI) and evaluates its potential for predicting MCI risk. We enrolled 90 ESRD patients with 2-year follow-up, categorized as MCI converters (MCI_C, n=48) and non-converters (MCI_NC, n=42). Brain networks were constructed using baseline rs-fMRI and high angular resolution diffusion imaging, focusing on regional structural-functional coupling (SFC). A Support Vector Machine (SVM) model was used to identify brain regions associated with cognitive decline. Mediation analysis was conducted to explore the relationship between kidney function, brain network reconfiguration, and cognition. MCI_C patients showed decreased network efficiency in the structural network and compensatory changes in the functional network. Machine learning models using multimodal network features predicted MCI with high accuracy (AUC=0.928 for training set, AUC=0.903 for test set). SHAP analysis indicated that reduced hippocampal SFC was the most significant predictor of MCI_C. Mediation analysis revealed that altered brain network topology, particularly hippocampal SFC, mediated the relationship between kidney dysfunction and cognitive decline. This study provides new insights into the link between kidney function and cognition, offering potential clinical applications for structural and functional MRI biomarkers.

When antispasmodics are unavailable, the periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER; called BLADE by Siemens Healthineers) or half Fourier single-shot turbo spin echo (HASTE) is clinically used in gynecologic MRI. However, their imaging qualities are limited compared to Turbo Spin Echo (TSE) with antispasmodics. Even with antispasmodics, TSE can be artifact-affected, necessitating a rapid backup sequence. This study aimed to investigate the utility of HASTE with deep learning reconstruction and variable flip angle evolution (iHASTE) compared to conventional sequences with and without antispasmodics. This retrospective study included MRI scans without antispasmodics for 79 patients who underwent iHASTE, HASTE, and BLADE and MRI scans with antispasmodics for 79 case-control matched patients who underwent TSE. Three radiologists qualitatively evaluated image quality, robustness to artifacts, tissue contrast, and uterine lesion margins. Tissue contrast was also quantitatively evaluated. Quantitative evaluations revealed that iHASTE exhibited significantly superior tissue contrast to HASTE and BLADE. Qualitative evaluations indicated that iHASTE outperformed HASTE in overall quality. Two of three radiologists judged iHASTE to be significantly superior to BLADE, while two of three judged TSE to be significantly superior to iHASTE. iHASTE demonstrated greater robustness to artifacts than both BLADE and TSE. Lesion margins in iHASTE had lower scores than BLADE and TSE. iHASTE is a viable clinical option in patients undergoing gynecologic MRI with anti-spasmodics. iHASTE may also be considered as a useful add-on sequence in patients undergoing MRI with antispasmodics.

To improve the prediction of immune checkpoint inhibitors (ICIs) efficacy in hepatocellular carcinoma (HCC), this study categorized the tumor immune microenvironment (TIME) into two types: immune-activated (IA), characterized by a high CD8 + score and high PD-L1 combined positive score (CPS), and non-immune-activated (NIA), encompassing all other conditions. We aimed to develop an MRI-based radiomics model to predict TIME types and validate its predictive capability for ICIs efficacy in HCC patients receiving anti-PD-1/PD-L1 therapy. The study included 200 HCC patients who underwent preoperative/pretreatment multiparametric contrast-enhanced MRI (Cohort 1: 168 HCC patients with hepatectomy from two centres; Cohort 2: 42 advanced HCC patients on anti-PD-1/PD-L1 therapy). In Cohort 1, after feature selection, clinical, intratumoral radiomics, peritumoral radiomics, combined radiomics, and clinical-radiomics models were established using machine learning algorithms. In cohort 2, the clinical-radiomics model's predictive ability for ICIs efficacy was assessed. In Cohort 1, the AUC values for intratumoral, peritumoral, and combined radiomics models were 0.825, 0.809, and 0.868, respectively, in the internal validation set, and 0.73, 0.759, and 0.822 in the external validation set; the clinical-radiomics model incorporating neutrophil-to-lymphocyte ratio, tumor size, and combined radiomics score achieved an AUC of 0.887 in the internal validation set, outperforming clinical model (P = 0.049), and an AUC of 0.837 in the external validation set. In cohort 2, the clinical-radiomics model stratified patients into low- and high-score groups, demonstrating a significant difference in objective response rate (p = 0.003) and progression-free survival (p = 0.031). The clinical-radiomics model is effective in predicting TIME types and efficacy of ICIs in HCC, potentially aiding in treatment decision-making.

HER2 expression is crucial for the application of HER2-targeted antibody-drug conjugates. This study aims to construct a predictive model by integrating multiparametric magnetic resonance imaging (mpMRI) based multimodal radiomics and the Vesical Imaging-Reporting and Data System (VI-RADS) score for noninvasive identification of HER2 status in bladder urothelial carcinoma (BUC). A total of 197 patients were retrospectively enrolled and randomly divided into a training cohort (n = 145) and a testing cohort (n = 52). The multimodal radiomics features were derived from mpMRI, which were also utilized for VI-RADS score evaluation. LASSO algorithm and six machine learning methods were applied for radiomics feature screening and model construction. The optimal radiomics model was selected to integrate with VI-RADS score to predict HER2 status, which was determined by immunohistochemistry. The performance of predictive model was evaluated by receiver operating characteristic curve with area under the curve (AUC). Among the enrolled patients, 110 (55.8%) patients were demonstrated with HER2-positive and 87 (44.2%) patients were HER2-negative. Eight features were selected to establish radiomics signature. The optimal radiomics signature achieved the AUC values of 0.841 (95% CI 0.779-0.904) in the training cohort and 0.794 (95%CI 0.650-0.938) in the testing cohort, respectively. The KNN model was selected to evaluate the significance of radiomics signature and VI-RADS score, which were integrated as a predictive nomogram. The AUC values for the nomogram in the training and testing cohorts were 0.889 (95%CI 0.840-0.938) and 0.826 (95%CI 0.702-0.950), respectively. Our study indicated the predictive model based on the integration of mpMRI-based radiomics and VI-RADS score could accurately predict HER2 status in BUC. The model might aid clinicians in tailoring individualized therapeutic strategies.

To develop and evaluate a physics-driven, saturation contrast-aware, deep-learning-based framework for motion artifact correction in CEST MRI. A neural network was designed to correct motion artifacts directly from a Z-spectrum frequency (Ω) domain rather than an image spatial domain. Motion artifacts were simulated by modeling 3D rigid-body motion and readout-related motion during k-space sampling. A saturation-contrast-specific loss function was added to preserve amide proton transfer (APT) contrast, as well as enforce image alignment between motion-corrected and ground-truth images. The proposed neural network was evaluated on simulation data and demonstrated in healthy volunteers and brain tumor patients. The experimental results showed the effectiveness of motion artifact correction in the Z-spectrum frequency domain (MOCO_Ω) compared to in the image spatial domain. In addition, a temporal convolution applied to a dynamic saturation image series was able to leverage motion artifacts to improve reconstruction results as a denoising process. The MOCO_Ω outperformed existing techniques for motion correction in terms of image quality and computational efficiency. At 3 T, human experiments showed that the root mean squared error (RMSE) of APT images decreased from 4.7% to 2.1% at 1 μT and from 6.2% to 3.5% at 1.5 μT in case of "moderate" motion and from 8.7% to 2.8% at 1 μT and from 12.7% to 4.5% at 1.5 μT in case of "severe" motion, after motion artifact correction. The MOCO_Ω could effectively correct motion artifacts in CEST MRI without compromising saturation transfer contrast.

Embolic protection devices (EPDs) used during carotid artery stenting (CAS) are crucial in reducing ischemic complications. Although minimizing the filter-type EPD movement is considered important, limited research has demonstrated this practice. We used an artificial intelligence (AI)-based device recognition technology to investigate the correlation between filter movements and ischemic complications. We retrospectively studied 28 consecutive patients who underwent CAS using FilterWire EZ (Boston Scientific, Marlborough, MA, USA) from April 2022 to September 2023. Clinical data, procedural videos, and postoperative magnetic resonance imaging were collected. An AI-based device detection function in the Neuro-Vascular Assist (iMed Technologies, Tokyo, Japan) was used to quantify the filter movement. Multivariate proportional odds model analysis was performed to explore the correlations between postoperative diffusion-weighted imaging (DWI) hyperintense lesions and potential ischemic risk factors, including filter movement. In total, 23 patients had sufficient information and were eligible for quantitative analysis. Fourteen patients (60.9 %) showed postoperative DWI hyperintense lesions. Multivariate analysis revealed significant associations between filter movement distance (odds ratio, 1.01; 95 % confidence interval, 1.00-1.02; p = 0.003) and high-intensity signals in time-of-flight magnetic resonance angiography with DWI hyperintense lesions. Age, symptomatic status, and operative time were not significantly correlated. Increased filter movement during CAS was correlated with a higher incidence of postoperative DWI hyperintense lesions. AI-based quantitative evaluation of endovascular techniques may enable demonstration of previously unproven recommendations. To the best of our knowledge, this is the first study to use an AI system for quantitative evaluation to address real-world clinical issues.